JPRN-jRCT2073200004
Suspended
Phase 1
Phase 1/2 clinical trial of the intratumoral administration of oncolytic virus for unresectable pancreatic cancer
Ido Akio0 sites24 target enrollmentApril 15, 2020
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Pancreatic cancer
- Sponsor
- Ido Akio
- Enrollment
- 24
- Status
- Suspended
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The patients with pancreatic tumors must meet the following eligibility criteria:
- •1\)Diagnosed histologically with pancreatic ductal carcinoma.
- •2\)Diagnosed with unresectable pancreatic cancer because of metastasis and/or vascular invasion.
- •3\)Primary standard treatment for unresectable pancreatic cancer failed.
- •If a patient who received radiation or chemoradiation therapy for locally advanced pancreatic cancer is judged to have failed the primary treatment due to metastasis without progression of pancreatic cancer or drug\-induced adverse events, the period after radiation must be at least one month.
- •4\)The long and short axes and height of the pancreatic lesion can be measured by computed tomography, and the investigational agent can be administered to the lesion.
- •5\)\>\= 20 years old.
- •6\)ECOG performance status (PS) is 0\-2\.
- •7\)The overall survival is expected to exceed three months.
- •8\)Main organ functions are maintained (according to the latest blood test performed within two weeks before registration):
Exclusion Criteria
- •1\)Patients with the following complications: Severe heart disease, severe respiratory disease, severe digestive disease, severe liver disease, uncontrolled diabetes, and infection requiring continuous treatment
- •2\)Patients with a history of penicillin or allergy to pigs or cattle (including milk).
- •3\)Patients with a disease that requires the administration of systemic immunosuppressants or steroids.
- •4\)For patients judged to have failed the primary therapy of radiation or chemoradiation, the interval after the therapy is \<\= 1 month (patients are still eligible if the reason for primary therapy failure is progression of pancreatic cancer).
- •5\)Patients with other currently active cancers (patients are still eligible if the other cancers are basal cell carcinoma, carcinoma in situ, superficial bladder cancer, or malignancies without metastasis or recurrence for more than five years and have been treated appropriately)
- •6\)Patients with an uncontrollable fever or pain due to the tumor.
- •7\)Patients with a history of gastroduodenal surgery or gastroduodenal stricture.
- •8\)Patients who are pregnant, breast\-feeding, or have a positive pregnancy test within one year after menopause.
- •9\)Patients who received any other unapproved drug within four weeks before giving their consent.
- •10\)Patients deemed inappropriate to include in the trial by the investigator.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Phase 1/2 clinical trial of the intratumoral administration of oncolytic virus for unresectable pancreatic cancerPancreatic cancerJPRN-UMIN000039854Kagoshima University24
Active, not recruiting
Phase 1
Phase 1b/2 Study of V937 Injected into Tumors in Combination with Intravenous (IV) PembrolizumabAdvanced/metastatic solid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-001908-42-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc185
Active, not recruiting
Phase 1
Phase 1b/2 Study of V937 Injected into Tumors in Combination with Intravenous (IV) PembrolizumabEUCTR2020-001908-42-PTMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc185
Active, not recruiting
Phase 1
Phase 1b/2 Study of V937 Injected into Tumors in Combination with Intravenous (IV) PembrolizumabEUCTR2020-001908-42-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.185
Completed
Phase 1
Phase 1b/2 Study of ITu V937 in Combination with PembrolizumabJPRN-jRCT2033200191ohata Nijiro185